O6U
Nirogacestat
Created: | 2023-08-23 |
Last modified: | 2024-11-11 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 76 |
Chiral Atom Count | 2 |
Bond Count | 78 |
Aromatic Bond Count | 11 |
Chemical Component Summary | |
---|---|
Name | Nirogacestat |
Systematic Name (OpenEye OEToolkits) | (2~{S})-2-[[(2~{S})-6,8-bis(fluoranyl)-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-~{N}-[1-[1-(2,2-dimethylpropylamino)-2-methyl-propan-2-yl]imidazol-4-yl]pentanamide |
Formula | C27 H41 F2 N5 O |
Molecular Weight | 489.644 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | CACTVS | 3.385 | CCC[CH](N[CH]1CCc2cc(F)cc(F)c2C1)C(=O)Nc3cn(cn3)C(C)(C)CNCC(C)(C)C |
SMILES | OpenEye OEToolkits | 2.0.7 | CCCC(C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C)NC2CCc3cc(cc(c3C2)F)F |
Canonical SMILES | CACTVS | 3.385 | CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc3cn(cn3)C(C)(C)CNCC(C)(C)C |
Canonical SMILES | OpenEye OEToolkits | 2.0.7 | CCC[C@@H](C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C)N[C@H]2CCc3cc(cc(c3C2)F)F |
InChI | InChI | 1.06 | InChI=1S/C27H41F2N5O/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35)/t20-,23-/m0/s1 |
InChIKey | InChI | 1.06 | VFCRKLWBYMDAED-REWPJTCUSA-N |
Drug Info: DrugBank
DrugBank ID | DB12005 |
---|---|
Name | Nirogacestat |
Groups |
|
Description | Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling.[A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling and thus impede the growth of desmoid tumors.[A262561] Nirogacestat was approved under the brand name OGSIVEO on November 27, 2023, by the FDA for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase 3 DeFi trial, where a confirmed objective response rate was observed to be 41% compared to 8% with the placebo.[L49036] |
Synonyms | Nirogacestat |
Brand Names | Ogsiveo |
Indication | Nirogacestat is indicated for adult patients with progressing desmoid tumors who require systemic treatment.[L48857] |
Categories |
|
CAS number | 1290543-63-3 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Gamma-secretase subunit APH-1B | MTAAVFFGCAFIAFGPALALYVFTIATEPLRIIFLIAGAFFWLVSLLISS... | unknown | modulator |
Nicastrin | MATAGGGSGADPGSRGLLRLLSFCVLLAGLCRGNSVERKIYIPLNKTAPC... | unknown | modulator |
Presenilin-1 | MTELPAPLSYFQNAQMSEDNHLSNTVRSQNDNRERQEHNDRRSLGHPEPL... | unknown | inhibitor |
Gamma-secretase subunit PEN-2 | MNLERVSNEEKLNLCRKYYLGGFAFLPFLWLVNIFWFFREAFLVPAYTEQ... | unknown | modulator |
Gamma-secretase subunit APH-1A | MGAAVFFGCTFVAFGPAFALFLITVAGDPLRVIILVAGAFFWLVSLLLAS... | unknown | modulator |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
PubChem | 46224413 |
ChEMBL | CHEMBL1770916 |
ChEBI | CHEBI:229217 |